Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma: The PERM Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PERM
- 20 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2018 Status changed from not yet recruiting to recruiting.
- 07 Jan 2016 Planned End Date changed from 1 Oct 2019 to 1 Feb 2020, as reported by ClinicalTrials.gov.